Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05262400 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.
Conditions Studied
Interventions
- DRUG PF-07220060 + PF-07104091 combination dose escalation
Study Locations (20)
California
- Administrative Address: UCLA Hematology/Oncology — Los Angeles
- Ronald Reagan UCLA Medical Center — Los Angeles
- UCLA Hematology/Oncology — Los Angeles
- UCLA Hematology / Oncology-Parkside — Santa Monica
- UCLA Hematology/Oncology-Santa Monica — Santa Monica
Other
- Centro Oncologico Korben — Buenos Aires
- Clínica Universitaria Reina Fabiola — Córdoba
- Fundación CORI para la Investigación y Prevención del Cáncer — La Rioja
Rio Grande do Sul
- ONCOSITE - Centro de Pesquisa Clinica em Oncologia — Ijuí
- Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa — Porto Alegre
- Centro de Pesquisa Clínica - Área Administrativa — Porto Alegre
Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas
- The University of Texas MD Anderson Cancer Center — Houston
Washington
- Swedish Medical Center — Seattle
- Swedish Medical Center — Seattle
Massachusetts
- Massachusetts General Hospital — Boston
Michigan
- START Midwest — Grand Rapids
Missouri
- Saint Luke's Cancer Institute — Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2026-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05262400
The ClinicalTrials.gov registry entry for NCT05262400 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which PF-07220060 + PF-07104091 combination dose escalation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05262400 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Other, Rio Grande do Sul. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05262400 about?
NCT05262400 is a clinical study titled "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Br...
What is the current status of trial NCT05262400?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-03-14. Estimated completion is 2026-08-23.
What conditions does trial NCT05262400 study?
This clinical trial studies the following conditions: Breast Cancer, Solid Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05262400?
The interventions under investigation include: PF-07220060 + PF-07104091 combination dose escalation (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05262400?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05262400 being conducted?
This trial has 20 study locations across California, Massachusetts, Michigan, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.